Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGES | O14684 | 2/20 | 0.52 |
| ▸ | GCGR | P47871 | 17/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | ADCY6 | O43306 | 1/20 | 0.39 |
| ▸ | ADCY3 | O60266 | 1/20 | 0.39 |
| ▸ | ADCY9 | O60503 | 1/20 | 0.39 |
| ▸ | ADCY5 | O95622 | 1/20 | 0.39 |
| ▸ | ADCY8 | P40145 | 1/20 | 0.39 |
| ▸ | ADCY7 | P51828 | 1/20 | 0.39 |
| ▸ | ADCY2 | Q08462 | 1/20 | 0.39 |
| ▸ | ADCY1 | Q08828 | 1/20 | 0.39 |
| ▸ | ADCY4 | Q8NFM4 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4228521 | 0.92 | PTGES (0.54) | PTGESGCGRLMNAMAPT | |
| SCHEMBL4228392 | 0.91 | PTGES (0.48) | PTGESGCGRLMNAMAPT | |
| SCHEMBL4226260 | 0.89 | PTGES (0.49) | PTGESGCGRLMNAMAPT | |
| SCHEMBL4227306 | 0.86 | PTGES (0.49) | PTGESGCGRLMNAMAPT | |
| SCHEMBL3578255 | 0.86 | PTGES (0.69) | PTGESGCGRLMNAMAPT | |
| SCHEMBL4218509 | 0.84 | PTGES (0.52) | PTGESLMNAMAPT | |
| SCHEMBL3006124 | 0.84 | PTGES (0.49) | PTGESGCGRLMNAMAPT | |
| SCHEMBL4228938 | 0.83 | PTGES (0.57) | PTGESLMNAMAPT | |
| SCHEMBL4223283 | 0.83 | PTGES (0.51) | PTGESGCGRLMNAMAPT | |
| SCHEMBL4224586 | 0.83 | PTGES (0.51) | PTGESGCGRLMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090042949-A1 | Indoles Useful in the Treatment of Inflammation | BIOLIPOX AB (SE) | 2009-02-12 | — | — | US | disclosed |
| EP-1838669-A1 | INDOLES USEFUL IN THE TREATMENT OF INFLAMMATION | Biolipox AB (SE) | 2007-10-03 | — | — | EP | disclosed |
| WO-2006077365-A1 | INDOLES USEFUL IN THE TREATMENT OF INFLAMMATION | BIOLIPOX AB (SE) | 2006-07-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090042949-A1 | Indoles Useful in the Treatment of Inflammation | IDO1, IDO2, AREG | PTGES 28/4885GCGR 675/4885LMNA 3630/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.